ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for monitor Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.

DPH Dechra Pharmaceuticals Plc

3,866.00
0.00 (0.00%)
Last Updated: 00:00:00
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Dechra Pharmaceuticals Plc LSE:DPH London Ordinary Share GB0009633180 ORD 1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 3,866.00 0.00 00:00:00
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
0 0 N/A 0

State Street Global Advisors Form 8.3 - Dechra Pharmaceuticals plc (8842Z)

16/01/2024 1:25pm

UK Regulatory


Dechra Pharmaceuticals (LSE:DPH)
Historical Stock Chart


From Dec 2023 to Dec 2024

Click Here for more Dechra Pharmaceuticals Charts.

TIDMDPH

RNS Number : 8842Z

State Street Global Advisors

16 January 2024

Rule 8.3

PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY

A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE

Rule 8.3 of the Takeover Code (the "Code")

   1.         KEY INFORMATION 
 
 (a) Full name of discloser:                                                 State Street Global Advisors & Affiliates 
 (b) Owner or controller of interests and short positions disclosed, if 
 different from 1(a): 
 The naming of nominee or vehicle companies is insufficient. For a trust, 
 the trustee(s), 
 settlor and beneficiaries must be named. 
                                                                            ------------------------------------------ 
 (c) Name of offeror/offeree in relation to whose relevant securities this 
 form relates:                                                                 Dechra Pharmaceuticals plc 
 Use a separate form for each offeror/offeree 
                                                                            ------------------------------------------ 
 (d) If an exempt fund manager connected with an offeror/offeree, state 
 this and specify identity 
 of offeror/offeree: 
                                                                            ------------------------------------------ 
 (e) Date position held/dealing undertaken:                                  15-January-2024 
 For an opening position disclosure, state the latest practicable date 
 prior to the disclosure 
                                                                            ------------------------------------------ 
 (f) In addition to the company in 1(c) above, is the discloser making       YES / NO / N/A 
 disclosures in respect                                                       If YES, specify which: 
 of any other party to the offer? 
 If it is a cash offer or possible cash offer, state "N/A"                    No 
                                                                            ------------------------------------------ 
 
   2.         POSITIONS OF THE PERSON MAKING THE DISCLOSURE 

If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.

(a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)

 
 Class of relevant security:                                                  1p ordinary 
                                                                                   Interests          Short positions 
                                                                             ---------------------  ------------------ 
                                                                               Number        %          Number      % 
                                                                             ----------             -------------  --- 
 (1) Relevant securities owned and/or controlled:                             1,313,243   1.15292% 
                                                                             ----------  ---------  -------------  --- 
 (2) Cash-settled derivatives: 
                                                                             ----------  ---------  -------------  --- 
 (3) Stock-settled derivatives (including options) and agreements to 
 purchase/sell: 
                                                                             ----------  ---------  -------------  --- 
 
   TOTAL:                                                                     1,313,243   1.15292% 
                                                                             ----------  ---------  -------------  --- 
 

All interests and all short positions should be disclosed.

Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).

   (b)        Rights to subscribe for new securities (including directors' and other employee options) 
 
 Class of relevant security in relation to which subscription right exists: 
 Details, including nature of the rights concerned and relevant percentages: 
 
 
   3.         DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE 

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

The currency of all prices and other monetary amounts should be stated.

   (a)        Purchases and sales 
 
 Class of relevant security   Purchase/sale   Number of securities   Price per unit 
 
 
   (b)        Cash-settled derivative transactions 
 
    Class of relevant       Product description      Nature of dealing         Number of reference      Price per unit 
         security                 e.g. CFD         e.g. opening/closing a           securities 
                                                    long/short position, 
                                                   increasing/reducing a 
                                                    long/short position 
 
 
   (c)        Stock-settled derivative transactions (including options) 
   (i)         Writing, selling, purchasing or varying 
 
   Class of       Product        Writing,      Number of       Exercise          Type       Expiry date   Option money 
   relevant     description    purchasing,     securities      price per         e.g.                        paid/ 
   security      e.g. call       selling,       to which         unit         American,                   received per 
                   option      varying etc.      option                        European                       unit 
                                                relates                          etc. 
 
 
   (ii)        Exercise 
 
   Class of relevant      Product description   Exercising/ exercised    Number of securities     Exercise price per 
        security            e.g. call option           against                                           unit 
 
 
   (d)        Other dealings (including subscribing for new securities) 
 
 Class of relevant security         Nature of dealing          Details   Price per unit (if applicable) 
                               e.g. subscription, conversion 
 
 
   4.         OTHER INFORMATION 
   (a)        Indemnity and other dealing arrangements 
 
 Details of any indemnity or option arrangement, or any agreement or understanding, formal 
  or informal, relating to relevant securities which may be an inducement to deal or refrain 
  from dealing entered into by the person making the disclosure and any party to the offer or 
  any person acting in concert with a party to the offer: 
  Irrevocable commitments and letters of intent should not be included. If there are no such 
  agreements, arrangements or understandings, state "none" 
 
   None 
 
   (b)        Agreements, arrangements or understandings relating to options or derivatives 
 
 Details of any agreement, arrangement or understanding, formal or informal, between the person 
  making the disclosure and any other person relating to: 
  (i) the voting rights of any relevant securities under any option; or 
  (ii) the voting rights or future acquisition or disposal of any relevant securities to which 
  any derivative is referenced: 
  If there are no such agreements, arrangements or understandings, state "none" 
 
   None 
 
   (c)        Attachments 
 
 Is a Supplemental Form 8 (Open Positions) attached?   No 
 
 
 Date of disclosure:    16-January-2024 
 Contact name:          Divya K 
                       ---------------- 
 Telephone number*:     +918067452364 
                       ---------------- 
 

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.

The Panel's Market Surveillance Unit is available for consultation in relation to the Code's disclosure requirements on +44 (0)20 7638 0129.

*If the discloser is a natural person, a telephone number does not need to be included, provided contact information has been provided to the Panel's Market Surveillance Unit.

The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk .

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

RETBXGDBXDBDGSL

(END) Dow Jones Newswires

January 16, 2024 08:25 ET (13:25 GMT)

1 Year Dechra Pharmaceuticals Chart

1 Year Dechra Pharmaceuticals Chart

1 Month Dechra Pharmaceuticals Chart

1 Month Dechra Pharmaceuticals Chart